[CAS NO. 25546-65-0] Ribostamycin
PRODUCTS SPECIFICATIONS [25546-65-0]
DESCRIPTION [25546-65-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 454.47 |
| Molecular Formula | C17H34N4O10 |
| SMILES | NC[C@H]([C@H]([C@@H]([C@H]1N)O)O)O[C@@H]1O[C@H]([C@H](C[C@H]([C@@H]2O)N)N)[C@@H]2O[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO |
Summary
Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic . Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI [1] [2] .
In Vitro
Ribostamycin inhibits
Borrelia burgdorferi
with a MIC
90
of 32 mg/L
[2]
.
Ribostamycin (1-100 μM, 0-15 min) inhibits the chaperone activity of PDI
[3]
.
Ribostamycin inhibits
Escherichia coli
strains with a MIC of 0.9-7.2 μM
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [4]
| Cell Line: | Escherichia coli strains |
| Concentration: | 0-64 μg/mL |
| Incubation Time: | 14 h |
| Result: | Inhibited Escherichia coli strains with a MIC of 0.9-7.2 μM. |
In Vivo
Ribostamycin (40 mg/kg, intramuscular injection, per day for 14 days) causes little nephrotoxicity in rats(evaluated by urinalysis)
[5]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Source
Streptomyces ribosidificus
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018 Apr 1;164:185-191.
- [2] Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17(3):203-8.
- [3] Horibe T, et al. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72.
- [4] Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020 Jul 29;11:1718.
- [5] Kitasato I, et al. Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis. Drugs Exp Clin Res. 1989;15(6-7):273-89.